bryan johnson semaglutide says GLP-1s might be a longevity drug. He’s not wrong about that — but then someone asked him if it’s okay to take one at a healthy weight, and he answered in one word. Yes. To a Bryan Johnson | SynBioBeta Speaker

Complete response letters have become uncommon for obesity drugs with large, well-run trial programs (FDA CDER)

Below: injectable, IV, and buccal protocols with documented dose ranges, delivery-route trade-offs, and reconstitution math for the full mechanism and age-decline research, see the glutathione peptide page

Data extraction and processing We analyzed FAERS reports from 2005 Q2 to 2024 Q3

While OTC alternatives remain uniform and untailored, genetic insights can support a more personalized conversation between you and your provider about whether prescription-strength options align with your metabolic profile